Browsing publications by Professor Stephen O'Brien

Newcastle AuthorsTitleYearFull text
Professor Stephen O'Brien
De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial2017
Professor Stephen O'Brien
Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia.2017
Professor Stephen O'Brien
De-escalation of tyrosine kinase inhibitor therapy is safe in chronic myeloid leukaemia in durable molecular response (>= mr3 for >= 12 months): initial results in the British DESTINY study2016
Dr Ed Schwalbe
Dr Kevin Windebank
Professor Stephen O'Brien
Dr Peter Carey
Professor Simon Bailey
et al.
The use of anthracyclines in the treatment of endemic Burkitt lymphoma2016
Corrine Hedgley
Professor Stephen O'Brien
PTCH1 expression at diagnosis predicts imatinib failure in chronic myeloid leukaemia patients in chronic phase2015
Leanne Cork
Corinne Hedgley
Dr Wendy Osborne
Gemma Gills
Ruth Bescoby
et al.
Assessment of Quality of Life in the NCRI Spirit 2 Study Comparing Imatinib with Dasatinib in Patients with Newly-Diagnosed Chronic Phase Chronic Myeloid Leukaemia2015
Dr Wendy Osborne
Professor Stephen O'Brien
Corinne Hedgley
Ruth Bescoby
SPIRIT 2: an NCRI randomised study comparing dasatinib with imatinib in patients with newly diagnosed chronic myeloid leukaemia-2 year follow up2015
Dr Samuel Moses
Professor Stephen O'Brien
Dr Tobias Menne
Dr Jonathan Wallis
Haemophagocytic lymphohistiocytosis following fludarabine/cyclophosphamide chemotherapy for chronic lymphocytic leukaemia2014
Professor Stephen O'Brien
Corinne Hedgley
Lynn Alaily
Dr Wendy Osborne
Spirit 2: An NCRI Randomised Study Comparing Dasatinib with Imatinib in Patients with Newly Diagnosed CML2014
Professor Stephen O'Brien
Corinne Hedgley
Dr Wendy Osborne
SPIRIT 2: an NCRI randomised study comparing dasatinib with imatinib in patients with newly diagnosed CML2014
12345678